Business Context and Reporting Period
This Form 8-K is filed by Novus Therapeutics, Inc. (not Eledon Pharmaceuticals, Inc., as indicated in the metadata) on July 11, 2019. The report covers events occurring on the date of the Company's annual meeting of stockholders, specifically regarding changes in the independent registered public accounting firm and the results of stockholder votes.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. However, it references historical financial conditions:
- Going Concern: The independent auditor's report for the fiscal year ended December 31, 2018, included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Audit Opinions: Reports for fiscal years 2017 and 2018 did not contain adverse opinions, disclaimers, or qualifications regarding accounting principles, aside from the going concern note.
Material Changes
The primary material change reported is the dismissal of Ernst & Young LLP (EY) as the Company's independent registered public accounting firm, effective immediately on July 11, 2019. Concurrently, the Audit Committee appointed KMJ Corbin & Company LLP as the new independent registered public accounting firm.
- No Disagreements: The Company reported no disagreements with EY regarding accounting principles, practices, financial statement disclosure, or auditing scope during the fiscal years ended December 31, 2018 and 2017, or the interim period through July 11, 2019.
- Consultation: The Company did not consult with KMJ regarding accounting principles or audit opinions prior to their appointment.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking guidance, financial outlook, or management commentary regarding future operations. The document focuses strictly on the procedural change of auditors and the ratification of the previous auditor at the annual meeting.
- Stockholder Vote: Stockholders voted to ratify EY for the fiscal year ending December 31, 2019 (11,848,525 For vs. 8,058 Against). However, the Audit Committee exercised its discretion to replace EY immediately following the vote.
- Director Elections: Two Class II directors, Keith A. Katkin and John S. McBride, were elected to three-year terms.
Important Facts for Investor Verification
- Verify the reasons for the sudden dismissal of EY immediately after stockholders ratified their appointment for the upcoming fiscal year.
- Review the "substantial doubt" regarding the Company's ability to continue as a going concern noted in the 2018 audit report.
- Confirm the qualifications and experience of the new auditor, KMJ Corbin & Company LLP, in auditing biopharmaceutical companies.
- Check for any subsequent filings that may provide updated financial data or clarify the transition between accounting firms.